ALIMERA SCIENCES INC
PharmaALIMERA SCIENCES INC is a pharmaceutical company focused on Ophthalmology. Key products include ILUVIEN.
ALIMERA SCIENCES INC's Key Drugs
ALIMERA SCIENCES INC's core commercial portfolio centers on ILUVIEN, YUTIQ, spanning Ophthalmology — its most strategically important drugs approved in the last 15 years.
ALIMERA SCIENCES INC's Recent FDA Approvals
New NDA/BLA approvals for ALIMERA SCIENCES INC over the last two years — novel drugs only, excluding generics and label supplements.
ALIMERA SCIENCES INC's Therapeutic Areas
ALIMERA SCIENCES INC's approved drugs and pipeline span 1 therapeutic area, led by Ophthalmology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALIMERA SCIENCES INC's Top Competitors
ALIMERA SCIENCES INC's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and OTSUKA ICU MEDCL. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALIMERA SCIENCES INC Pipeline Snapshot
ALIMERA SCIENCES INC has 7 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 2 Phase 2 and 4 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ILUVIEN leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/1 completed
- • Speed: N/A months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges